Cargando…

Assessment of Immune and Clinical Response in Patients with Mucosal Leishmaniasis Treated with Pentavalent Antimony and Pentoxifylline

Mucosal leishmaniasis (ML) is a severe form of tegumentary leishmaniasis associated with a persistent inflammatory response. High levels of TNF, IFN-γ, CXCL9 and CXCL10 are found in ML patients, and the association of pentoxifylline with antimony is more effective in decreasing the healing time in M...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cincura, Carolina, Costa, Rubia S., De Lima, Clara Monica F., Oliveira-Filho, Jamary, Rocha, Paulo Novis, Carvalho, Edgar M., Lessa, Marcus M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9696819/ https://www.ncbi.nlm.nih.gov/pubmed/36422934 http://dx.doi.org/10.3390/tropicalmed7110383

Ejemplares similares

A Pilot Randomized Clinical Trial: Oral Miltefosine and Pentavalent Antimonials Associated With Pentoxifylline for the Treatment of American Tegumentary Leishmaniasis
por: Martins, Sofia Sales, et al.
Publicado: (2021)

New World Cutaneous Leishmaniasis Treated with Intralesional Injection of Pentavalent Antimony
por: Shin, Ji Yeon, et al.
Publicado: (2013)

High Anti-Leishmania IgG Antibody Levels Are Associated With Severity of Mucosal Leishmaniasis
por: de Lima, Clara Mônica F., et al.
Publicado: (2021)

Renal function evaluation in patients with American Cutaneous Leishmaniasis after specific treatment with pentavalent antimonial
por: Oliveira, Rodrigo A, et al.
Publicado: (2012)

Efficacy of pentavalent antimoniate intralesional infiltration therapy for cutaneous leishmaniasis: A systematic review
por: Brito, Nayara Castelano, et al.
Publicado: (2017)

The Pentavalent Antimony Compounds in Tropical Medicine
por: Schmidt, Hans
Publicado: (1928)

American tegumentary leishmaniasis: severe side effects of pentavalent antimonial in a patient with chronic renal failure
por: Marques, Sílvio Alencar, et al.
Publicado: (2019)

Pentavalent Antimonials Combined with Other Therapeutic Alternatives for the Treatment of Cutaneous and Mucocutaneous Leishmaniasis: A Systematic Review
por: Berbert, Taisa Rocha Navasconi, et al.
Publicado: (2018)

Mucosal leishmaniasis: epidemiological and clinical aspects
por: Miranda Lessa, Marcus, et al.
Publicado: (2015)

Pentavalent Antimonials: New Perspectives for Old Drugs
por: Frézard, Frédéric, et al.
Publicado: (2009)

A retrospective cohort study of the effectiveness and adverse events of intralesional pentavalent antimonials in the treatment of cutaneous leishmaniasis
por: Rodrigues, Bruna Côrtes, et al.
Publicado: (2020)

The Extraordinary Case of a Woman with a 30-Year-Long Diffuse Leishmaniasis Cured with One Single Ampoule of Intranasal Pentavalent Antimoniate
por: Gonçalves, Sheila V. C. B., et al.
Publicado: (2023)

Mixed Antimony(V) Complexes with Different Sugars to Modulate the Oral Bioavailability of Pentavalent Antimonial Drugs
por: Ferreira, Weverson A., et al.
Publicado: (2014)

First-Line Therapy for Human Cutaneous Leishmaniasis in Peru Using the TLR7 Agonist Imiquimod in Combination with Pentavalent Antimony
por: Miranda-Verastegui, Cesar, et al.
Publicado: (2009)

In Vitro Reduced Susceptibility to Pentavalent Antimonials of a Leishmania infantum Isolate from a Human Cutaneous Leishmaniasis Case in Central Italy
por: Diotallevi, Aurora, et al.
Publicado: (2021)

Reactions Following the Administration of the Pentavalent Compounds of Antimony: An Analysis of Cases Reported by Several Correspondents
por: Napier, L. Everard
Publicado: (1926)

CpG ODN D35 improves the response to abbreviated low-dose pentavalent antimonial treatment in non-human primate model of cutaneous leishmaniasis
por: Thacker, Seth G, et al.
Publicado: (2020)

“Cheaper and better”: Societal cost savings and budget impact of changing from systemic to intralesional pentavalent antimonials as the first-line treatment for cutaneous leishmaniasis in Bolivia
por: Eid Rodríguez, Daniel, et al.
Publicado: (2019)

In vitro susceptibility to pentavalent antimony in Leishmania infantum strains is not modified during in vitro or in vivo passages but is modified after host treatment with meglumine antimoniate
por: Carrió, Jaume, et al.
Publicado: (2002)

Pharmacometabolomics of Meglumine Antimoniate in Patients With Cutaneous Leishmaniasis
por: Vargas, Deninson Alejandro, et al.
Publicado: (2019)

Alpha-lipoic acid does not improve olfactory training results in olfactory loss due to COVID-19: a double-blind randomized trial
por: Figueiredo, Lorena Pinheiro, et al.
Publicado: (2023)

Effects of Meglumine Antimoniate Treatment on Cytokine Production in a Patient with Mucosal Leishmaniasis and Chagas Diseases Co-Infection
por: Rezende-Oliveira, Karine, et al.
Publicado: (2020)

Efficacy of intralesional meglumine antimoniate in the treatment of canine tegumentary leishmaniasis: A Randomized controlled trial
por: Lago, Jamile, et al.
Publicado: (2023)

Pentoxifylline in the Treatment of Cutaneous Leishmaniasis: A Randomized Clinical Trial in Colombia
por: Castro, Maria del Mar, et al.
Publicado: (2022)

Geographic Clustering of Leishmaniasis in Northeastern Brazil
por: Schriefer, Albert, et al.
Publicado: (2009)

Correction: Efficacy of intralesional meglumine antimoniate in the treatment of canine tegumentary leishmaniasis: A Randomized controlled trial
por: Lago, Jamile, et al.
Publicado: (2023)

Use of Antimony in the Treatment of Leishmaniasis: Current Status and Future Directions
por: Haldar, Arun Kumar, et al.
Publicado: (2011)

Antimony to Cure Visceral Leishmaniasis Unresponsive to Liposomal Amphotericin B
por: Morizot, Gloria, et al.
Publicado: (2016)

Neurological toxicity due to antimonial treatment for refractory visceral leishmaniasis
por: Maristany Bosch, Marta, et al.
Publicado: (2021)

Towards a standard protocol for antimony intralesional infiltration technique for cutaneous leishmaniasis treatment
por: da Silva, Rosiana Estéfane, et al.
Publicado: (2018)

Prediction Score for Antimony Treatment Failure in Patients with Ulcerative Leishmaniasis Lesions
por: Valencia, Cristian, et al.
Publicado: (2012)

Ramsey hunt syndrome after antimonial treatment for American Cutaneous Leishmaniasis
por: Cavalcante, Melissa de Sousa Melo, et al.
Publicado: (2020)

Cytotoxic activity in cutaneous leishmaniasis
por: Campos, Taís M, et al.
Publicado: (2017)

Voice Disorders in Mucosal Leishmaniasis
por: Ruas, Ana Cristina Nunes, et al.
Publicado: (2014)

Nutritional status in patients with cutaneous leishmaniasis and a study of the effects of zinc supplementation together with antimony treatment
por: Guzman-Rivero, Miguel, et al.
Publicado: (2014)

Alterations in Evoked Otoacoustic Emissions by the Use of Meglumine Antimoniate in American Tegumentary Leishmaniasis Patients
por: de Oliveira Bezerra, Débora Cristina, et al.
Publicado: (2017)

The role of mucosal-associated invariant T cells in visceral leishmaniasis
por: Moreira, Marcela de Lima, et al.
Publicado: (2022)

Comparison of Oral Zinc Sulfate with Systemic Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis
por: Yazdanpanah, Mohamad Javad, et al.
Publicado: (2011)

RESOLUTION OF CUTANEOUS LEISHMANIASIS AFTER ACUTE ECZEMA DUE TO INTRALESIONAL MEGLUMINE ANTIMONIATE
por: Vasconcellos, Erica de Camargo Ferreira e, et al.
Publicado: (2014)

Risk factors for antimony treatment failure in American Cutaneous Leishmaniasis in Northwestern-Argentina
por: García-Bustos, María F., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hj5ft3a8v763q9p145pd2anvnr